KYMR Valuation

Kymera Therapeutics Inc

Add to Watchlist

Advanced Chart

58.660

-2.34(-3.836%)1D

KYMR Relative Valuation

KYMR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KYMR is overvalued; if below, it's undervalued.

Historical Valuation

Kymera Therapeutics Inc (KYMR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 58.66 is considered Overvalued compared with the five-year average of -17.69. The fair price of Kymera Therapeutics Inc (KYMR) is between 25.45 to 47.92 according to relative valuation methord. Compared to the current price of 58.66 USD , Kymera Therapeutics Inc is Overvalued By 22.42%.

Relative Value

Fair Zone

25.45-47.92

Current Price：58.66

22.42%

Overvalued

-14.98

Trailing

Forward

-11.63

EV/EBITDA

Kymera Therapeutics Inc. (KYMR) has a current EV/EBITDA of -11.63. The 5-year average EV/EBITDA is -15.53. The thresholds are as follows: Strongly Undervalued below -51.24, Undervalued between -51.24 and -33.39, Fairly Valued between 2.32 and -33.39, Overvalued between 2.32 and 20.17, and Strongly Overvalued above 20.17. The current Forward EV/EBITDA of -11.63 falls within the Historic Trend Line -Fairly Valued range.

-10.10

EV/EBIT

Kymera Therapeutics Inc. (KYMR) has a current EV/EBIT of -10.10. The 5-year average EV/EBIT is -11.75. The thresholds are as follows: Strongly Undervalued below -38.26, Undervalued between -38.26 and -25.01, Fairly Valued between 1.50 and -25.01, Overvalued between 1.50 and 14.76, and Strongly Overvalued above 14.76. The current Forward EV/EBIT of -10.10 falls within the Historic Trend Line -Fairly Valued range.

58.66

Kymera Therapeutics Inc. (KYMR) has a current PS of 58.66. The 5-year average PS is 33.13. The thresholds are as follows: Strongly Undervalued below 5.04, Undervalued between 5.04 and 19.09, Fairly Valued between 47.17 and 19.09, Overvalued between 47.17 and 61.21, and Strongly Overvalued above 61.21. The current Forward PS of 58.66 falls within the Overvalued range.

-16.21

P/OCF

Kymera Therapeutics Inc. (KYMR) has a current P/OCF of -16.21. The 5-year average P/OCF is -28.78. The thresholds are as follows: Strongly Undervalued below -112.89, Undervalued between -112.89 and -70.83, Fairly Valued between 13.28 and -70.83, Overvalued between 13.28 and 55.33, and Strongly Overvalued above 55.33. The current Forward P/OCF of -16.21 falls within the Historic Trend Line -Fairly Valued range.

-14.86

P/FCF

Kymera Therapeutics Inc. (KYMR) has a current P/FCF of -14.86. The 5-year average P/FCF is -17.70. The thresholds are as follows: Strongly Undervalued below -46.94, Undervalued between -46.94 and -32.32, Fairly Valued between -3.08 and -32.32, Overvalued between -3.08 and 11.53, and Strongly Overvalued above 11.53. The current Forward P/FCF of -14.86 falls within the Historic Trend Line -Fairly Valued range.

Kymera Therapeutics Inc (KYMR) has a current Price-to-Book (P/B) ratio of 4.45. Compared to its 3-year average P/B ratio of 3.33 , the current P/B ratio is approximately 33.62% higher. Relative to its 5-year average P/B ratio of 4.51, the current P/B ratio is about -1.45% higher. Kymera Therapeutics Inc (KYMR) has a Forward Free Cash Flow (FCF) yield of approximately -0.05%. Compared to its 3-year average FCF yield of -9.35%, the current FCF yield is approximately -99.42% lower. Relative to its 5-year average FCF yield of -7.08% , the current FCF yield is about -99.23% lower.

4.45

P/B

Median3y

3.33

Median5y

4.51

-0.05

FCF Yield

Median3y

-9.35

Median5y

-7.08

Competitors Valuation Multiple

The average P/S ratio for KYMR's competitors is 44.26, providing a benchmark for relative valuation. Kymera Therapeutics Inc Corp (KYMR) exhibits a P/S ratio of 58.66, which is 32.53% above the industry average. Given its robust revenue growth of -26.12%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

KYMR.O

Kymera Therapeutics Inc

Apogee Therapeutics Inc

Performance Decomposition

Market capitalization of KYMR increased by 25.21% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.67K to -2.97K.

The secondary factor is the Revenue Growth, contributed -26.12%to the performance.

Overall, the performance of KYMR in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-26.12%

3.74M → 2.76M

Revenue Growth

77.99%

-1.67K → -2.97K

Margin Expansion

-26.66%

-22.23 → -16.31

P/E Change

25.21%